Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK -rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
Gadgeel, Shirish M, MD, Gandhi, Leena, MD, Riely, Gregory J, MD, Chiappori, Alberto A, MD, West, Howard L, MD, Azada, Michele C, MPH, Morcos, Peter N, PharmD, Lee, Ruey-Min, MD, Garcia, Linta, PharmD, Yu, Li, PhD, Boisserie, Frederic, MSc, Di Laurenzio, Laura, PhD, Golding, Sophie, MSc, Sato, Jotaro, MS, Yokoyama, Shumpei, MS, Tanaka, Tomohiro, MS, Ou, Sai-Hong Ignatius, Dr
Published in The lancet oncology (01.09.2014)
Published in The lancet oncology (01.09.2014)
Get full text
Journal Article